FMA
IBB icon

FNY Managed Accounts’s iShares Biotechnology ETF IBB Stock Holding History

FNY Managed Accounts’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12
Closed -$1.38K – 146
2016
Q3 		$1.38K Buy
+12
New +$1.14K ﹤0.01% 393

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FNY Managed Accounts's IBB Position: Q1 2018 in Review

FNY Managed Accounts sold out of iShares Biotechnology ETF (IBB) in Q1 2018, closing a stake of 4,400 shares — an estimated $469K sold.

FNY Managed Accounts first reported a position in IBB in Q1 2014 and held it in 7 quarters. The position peaked at $472K in Q3 2015. 608 funds tracked by Wall St. Rank hold IBB as of Q1 2018.

  • FNY Managed Accounts reported no remaining iShares Biotechnology ETF position as of Q1 2018 after selling out during the quarter.
  • FNY Managed Accounts sold 4,400 iShares Biotechnology ETF shares in Q1 2018, an estimated $469K.
  • FNY Managed Accounts first reported a position in iShares Biotechnology ETF in Q1 2014 and held it in 7 quarters.
  • FNY Managed Accounts's iShares Biotechnology ETF position peaked at $472K in Q3 2015.
  • 608 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.